RxDoctor Payments Data

Bruce Haik, MD

Cardiovascular Disease · Livingston, NJNPI 1023018520

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.6%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Edwards Lifesciences at 36.0% of the total.

$16,136in general payments, 2019–2025

Across 194 payments — averaging $83.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$6K
  • Abbott$2K
  • Medtronic$2K
  • Abiomed$2K
  • Philips North America LLC$1K
  • Boston Scientific$1K
  • plus $2K from 22 others
$199,742in research payments, 2019–2025

Across 49 payments — averaging $4076.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$200K

What the payments were for

  • Travel & lodging$7,27845%
  • Food & beverage$8,65354%
  • Education$320%
  • Entertainment$1731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,136 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$76,788
Medicare patients
116
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Livingston

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →